Cipla shares jump 6% after Q1FY26 profit, broker upgrades

Stock hits new highs after earnings

Cipla shares climbed about 6% over the last two trading sessions, touching a high of Rs 1,575 on the BSE on Monday. The move followed the company’s Q1FY26 earnings, which showed year-on-year improvement in profitability. Brokerage commentary after the results also turned supportive, with multiple target-price revisions. Some estimates went as high as Rs 1,875 per share, pointing to potential upside from recent levels. The stock’s rise was presented as earnings-driven, rather than linked to a single corporate announcement.

Q1FY26 profit growth sets the tone

For the quarter ended June 2025, Cipla reported a 10% year-on-year increase in consolidated profit after tax (PAT) to Rs 1,298 crore. In the same quarter last year, consolidated PAT stood at Rs 1,178 crore. The reported improvement supported the immediate positive reaction in the stock. The earnings print also became the main reference point for brokerage updates that followed.

Brokerages raise targets, ratings remain mixed

Post-results, several brokerage houses revised their target prices for Cipla. Antique maintained a ‘Buy’ rating and raised its target to Rs 1,875 from Rs 1,760. Nuvama retained a ‘Hold’ rating while increasing its target to Rs 1,651 from Rs 1,620. Choice Broking upgraded the stock rating to ‘Add’ and assigned a target of Rs 1,620, compared to Rs 1,445 referenced for Q4FY25.

Why broker target changes matter for the stock

Target-price revisions often influence near-term positioning, particularly after results when investor attention is high. In Cipla’s case, the revised targets clustered in a broad range, from the low Rs 1,600s to Rs 1,875. The range highlights that while some analysts see room for further gains, others remain more conservative on valuation or earnings trajectory. The mixed stance is also visible in the ratings, which include Buy, Hold, and Add.

Reuters: North America sales lift profits, stock sets record

In a separate Reuters report, Cipla was described as the third-largest generic pharmaceutical manufacturer in India by revenue and as having exceeded profit projections for the first quarter. Reuters attributed the stronger profit to increased sales in the North American market and noted that the stock climbed to a historic peak. The report said Cipla shares rose 6.7% to a new high of 1,600 rupees after the announcement. It also cited LSEG data showing analyst expectations of 11.10 billion rupees for the quarter, and stated the reported profit exceeded that forecast.

India market performance: a key data point

Reuters also reported that revenue from India, Cipla’s second-largest market, increased 10% to 28.98 billion rupees. In normalized terms, that equals Rs 2,898 crore. For investors tracking Cipla’s domestic franchise, the India growth figure is an important signal, particularly because the local market often supports base volumes and brand-led momentum.

Flashback: earlier market cycles around COVID products

The broader dataset around Cipla includes earlier pandemic-era developments. Cipla had said it doubled production of the COVID-19 medication remdesivir to meet “unprecedented demand,” according to a statement cited by Reuters. In separate reporting, Cipla launched remdesivir under the brand name Cipremi at Rs 4,000 per vial and aimed to supply over 80,000 vials within the first month. Official sources were also cited in earlier coverage saying India’s drug regulator permitted Hetero and Cipla to manufacture and market remdesivir for restricted emergency use for hospitalised COVID-19 patients.

What older financial snapshots show

Some older research excerpts referenced steady operating metrics in a prior period. One note mentioned sales up 6% year-on-year to Rs 5,478.9 crore and EBITDA of Rs 1,231 crore, with EBITDA margin at 22.5% in Q3FY22. Another historical section referenced earlier target prices such as Rs 1,100 and Rs 965 in older reports, underscoring how analyst views and market price levels have shifted across cycles.

Key numbers and brokerage targets at a glance

Market impact and what investors are tracking

The immediate market impact was visible in Cipla’s quick move to new highs after the Q1FY26 earnings release. The profit growth to Rs 1,298 crore offered a clear anchor for the rally, while upgrades and target hikes widened the discussion on valuation. Investors are also likely to track whether strength in the North American market, as cited by Reuters, remains supportive in subsequent quarters. At the same time, the reported 10% growth in India revenue to Rs 2,898 crore provides a measurable indicator of domestic demand trends.

Conclusion

Cipla’s latest move was driven by a combination of Q1FY26 profit growth and a fresh round of brokerage target revisions, with the highest target at Rs 1,875. With ratings ranging from Buy to Hold and Add, the post-results narrative is supportive but not uniform. The next set of quarterly numbers and any further broker updates will be key reference points for how expectations evolve.